With more than 25 years of experience in the life sciences industry, Mike has held global leadership positions in both clinical development and life sciences software companies. Given this experience, he is highly experienced in the use of technology and understands its impact in simplifying the process of developing and delivering novel therapies and making them more accessible to patients around the world. He has worked with many biotech and pharmaceutical companies to develop clinical pathways that deliver upon the ultimate commercial goals required to ensure success for all stakeholders. Mike speaks at many global industry events to promote the idea of innovation in healthcare and to encourage a greater level of partnership between healthcare stakeholders.
Articles by Mike Ryan
Successfully Navigating Global Commercialization- A View from the C-Suite and Global Commercial Leaders
Launching in today’s unpredictable market is a journey with new challenges around every corner. While product pipelines are rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build effective commercialization infrastructures, think globally, and launch products at unprecedented speeds, which comes at a steep price. In this […]
Launching in the EU/U.K.: The 7-Step Countdown to Success
THE LAUNCH Eager to explore the vast potential of launching your product in the EU/UK? While the mission is challenging, thorough preparations can ensure a smooth route to success. You only get one chance to launch, and studies have shown that two-thirds of launches did not reach their projected sales. If your launch is sub-optimal […]
The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric
Are you interested in the rapidly evolving pharmaceutical landscape? Do you want to understand the paradigm shift in global commercialization strategies? If so, we have just the resource for you! Download our latest article titled “The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric”. This comprehensive guide provides insights into: The need for a unified, […]
In-Depth with an Industry Leader: Global Launch Ambitions and Paradigm Shifts
Biotech enterprises, driven by the dual goals of treating a maximum patient population and ensuring a robust return on investment, must strategically navigate the complex landscape of global commercialization. Although the United States remains a crucial first market, most industry commentators agree that a nuanced strategy prioritizing global expansion is imperative. From a market size […]
European Parliament’s Revision of the General Pharmaceutical Legislation
The European Parliament has adopted a revision of the general pharmaceutical legislation, repealing and amending previous legislation with a set of compromise amendments. According to the European Commission, it has been called “the largest reform in over 20 years.” In this POV, EVERSANA’s experts, Mike Ryan, GM, Europe and Monique Martin, SVP, Value and Evidence, […]
Adapting to Change: Examining the Implications of New EU Regulations on Commercialisation from the Perspectives of Patients, Providers, and Pharma Companies
In April, the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) 2022 Patient W.A.I.T Indicator found that the average rate of availability for pharmaceuticals in Europe is 45%, down 2% on the previous year. Additionally, the access gap between the highest and lowest country was found to be 83% in the 4-year cohort, and 80% […]
Successfully Navigating Self-Commercialisation in Europe
Introduction As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,, Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat patients and maximise the value of their products. However, the challenges of entering this market, particularly in terms of […]
Successful Launches in Europe: Complex, but Not Complicated?
Europe represents a major pharmaceutical market – it accounts for 22% of the global market, second only to the U.S. in terms of market size and has a large population of over 500 million. Understandably, pharmaceutical and biotechnology companies looking to maximise their revenue consider Europe to be a key focus[1]. Indeed, looking at first-time […]
The Future of Pharma – A Provocative Perspective
In this episode of AI For Pharma Growth, Dr. Andree Bates is joined by Mike Ryan, Vice President, Europe, EVERSANA. They discuss the future of pharma and the impact of recent advancements in healthcare. The industry is facing a unique moment, with technology opening up new possibilities for medical interventions and a greater focus on […]
New Medicines, New Access, New Frontiers
How psychedelics, cell therapies and other innovations are driving regulatory reform and new patient access Science is improving exponentially. What’s now possible, through new medicines, and entirely new categories of medicine, could only be dreamt of just a decade ago. Doctors and patients are naturally excited about the oncoming pipeline. But while science improves exponentially, […]
A Partnership Q&A with EVERSANA and Shorla Pharma
As industry and patient needs progress beyond traditional commercialization models, new models are needed to deliver products to patients quicker, especially when launching in international markets. Still asking yourself how to execute on a global pharmaceutical product launch? EVERSANA has the answer to this question and others that you’ll have when choosing a commercialization partner. In this Q&A, EVERSANA’s Mike Ryan, Executive Vice President, EMEA, and Sharon Cunningham, CEO […]
Why Launching in Europe Is Unlike Launching Anywhere Else
Today, there are more than half a billion people in the European Union (EU) and United Kingdom (U.K.). Passing over this part of the globe puts patients and manufacturers at risk for negative outcomes. Launching a new therapy in the EU and U.K. has traditionally involved complex navigation of service providers, price sequencing and the […]
Considering Commercial Success During Clinical Development: Maintaining a Global Perspective
Although commercial success is the ultimate goal of pharmaceutical research and development (R&D), many new treatments do not meet expectations and fail to achieve broad global reimbursement after initial regulatory approval., This causes therapies to underperform across international markets and, more importantly, limits access for patients in need. For example, only 56% of all new drugs approved by the European Medicines Agency (EMA) […]
WEBINAR: Yes EU can! How novel treatments can avoid complexity and commercialize with impact across the European continent
Europe has a population of more than 450 million people, yet most manufacturers consider the U.S. the primary market for launch. In this webinar, EVERSANA’s Mike Ryan, Executive Vice President, Europe, discusses with other industry leaders how the EU’s landscape is changing in order for European states to increasingly become a priority market for commercialization. This […]
WEBINAR: The New Path to European Pharmaceutical Commercialisation
Global healthcare and life sciences innovation continues to surge at an unprecedented rate. External disrupters such as Brexit, GDPR, new regulatory guidance, such as the Pharmaceutical Strategy for Europe, and the COVID-19 pandemic, are driving pharma and healthcare leaders to reevaluate long-standing strategies. If pharma companies want to remain globally relevant and competitive, they must reassess commercialisation strategies – particularly related to clinical […]
Change Is Happening in the EU: What Pharma Companies Need to Know About the European Union’s New Pharmaceutical Strategy
For the first time, the European Union is undergoing a major overhaul of its pharmaceutical industry with the new Pharmaceutical Strategy for Europe, which was launched in late 2020. Through this strategy, the European Union (EU) is making changes to its infrastructure with the goal of building a holistic, patient-centered, forward-looking pharmaceutical landscape for all EU member […]
A New Pharmaceutical Strategy for Europe
In late November, the European Commission announced the adoption of a new healthcare plan – the Pharmaceutical Strategy for Europe. This plan aims to strengthen the European Health Union while ensuring affordable patient access across the entire European Union and supporting sustainable innovation for pharmaceutical industries. What’s Changing, and Why? Until now, patient access and […]
Looking To Launch Or Commercialise In The US?
Launching a product is a serious undertaking, requiring a seamless approach to building a commercialisation strategy that includes all the variables needed to maximise the investment across the product’s lifecycle. Nowhere is this more true than the world’s largest market, the United States (US). We know that a successful product launch is critical to maximising […]
Patient Recruitment & Retention: A Perspective From “The Other Side” [Webinar]
[Webinar: 23 Minutes] With over 20 years experience on the clinical research arena, Mike Ryan shares the importance of patient engagement from the clinical trial all the way across the drug development continuum. He highlights that although some patients might not qualify for the clinical trial, they should continue to be relevant as future clients/patients […]
Increase Your Speed to Market
Commercial Strategies for a Successful Product Launch. With the launch of new blockbuster drugs becoming less frequent, there is increased scrutiny on the importance and success of clinical trials, mandatory to determining the safety and efficacy of a developing product. The road to commercialization is daunting – the process of bringing a product to market […]
“Ask the Expert” About Digital Therapeutics
The promise of digital health – from wearables to mobile health apps – could revolutionize healthcare by improving adherence, reducing costs, and making treatments more personalized. Mike Ryan shares insight on the opportunity to set a commercialization standard in the digital therapeutics market that meets customer need, works with regulators and payors, and defines how […]
Ask the Expert – Digital Therapeutics
From reimbursement strategies, distribution, dispensing, patient engagement and adherence programs, EVERSANA offers integrated solutions to alleviate the barriers facing the adoption of digital therapeutics. Mike Ryan, Executive Vice President of Europe and Asia Pacific, discusses how EVERSANA is leading the commercialization of digital therapeutics with an innovative and nimble commercial model valuable to patients, providers […]